Phacilitate Leaders World

Sponsors & Exhibitors

Regenerative Outcomes Foundation

As an extension of his efforts to create "opportunities for healing" for patients seeking regenerative health services, Doug Oliver founded The Regenerative Outcomes Foundation. Using the patient position to inspire and educate, the Foundation is committed to elevating the privilege of the patient voice, and supporting all stakeholders, whether public or private interest, who define the regenerative medicine movement, and providing them new ways of placing patients more squarely at the"adult table" where the real decisions are made, and actively contributing to shared goals by providing regulatory guidance to biotechnology innovators and physician groups, researching behavioral impacts on patient outcomes, interviewing thought leaders, advancing a registry, and crafting a future cash grant program for patients participating in regenerative medicine clinical trials.

Visit Website
View all Sponsors & Exhibitors
Loading
Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
    EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
    Dendreon
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman
    GSK